ES2588738T3 - Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas - Google Patents
Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas Download PDFInfo
- Publication number
- ES2588738T3 ES2588738T3 ES09727698.4T ES09727698T ES2588738T3 ES 2588738 T3 ES2588738 T3 ES 2588738T3 ES 09727698 T ES09727698 T ES 09727698T ES 2588738 T3 ES2588738 T3 ES 2588738T3
- Authority
- ES
- Spain
- Prior art keywords
- consensus
- nucleic acid
- seq
- protein
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract description 49
- 102000039446 nucleic acids Human genes 0.000 title abstract description 32
- 108020004707 nucleic acids Proteins 0.000 title abstract description 30
- 108090000623 proteins and genes Proteins 0.000 title description 69
- 102000004169 proteins and genes Human genes 0.000 title description 47
- 238000000034 method Methods 0.000 title description 5
- 239000000203 mixture Substances 0.000 title description 5
- 108091035707 Consensus sequence Proteins 0.000 title description 4
- 241001502567 Chikungunya virus Species 0.000 title description 2
- 239000012634 fragment Substances 0.000 abstract description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 18
- 230000002163 immunogen Effects 0.000 abstract description 14
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 abstract description 13
- 108090000565 Capsid Proteins Proteins 0.000 abstract description 9
- 102100023321 Ceruloplasmin Human genes 0.000 abstract description 9
- 150000001413 amino acids Chemical class 0.000 abstract description 8
- 101710125507 Integrase/recombinase Proteins 0.000 abstract description 6
- 230000014509 gene expression Effects 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 210000000234 capsid Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 230000028993 immune response Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000008488 polyadenylation Effects 0.000 description 8
- 102100034353 Integrase Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108010078428 env Gene Products Proteins 0.000 description 7
- 230000008713 feedback mechanism Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 229940124551 recombinant vaccine Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 238000011510 Elispot assay Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 101001050984 Apple stem grooving virus (strain Korea) Putative movement protein Proteins 0.000 description 1
- 101001050983 Apple stem grooving virus (strain P-209) Probable movement protein Proteins 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- -1 a-interferon Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4266108P | 2008-04-04 | 2008-04-04 | |
| US42661P | 2008-04-04 | ||
| PCT/US2009/039656 WO2009124312A2 (en) | 2008-04-04 | 2009-04-06 | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2588738T3 true ES2588738T3 (es) | 2016-11-04 |
Family
ID=41136129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09727698.4T Active ES2588738T3 (es) | 2008-04-04 | 2009-04-06 | Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8852609B2 (https=) |
| EP (1) | EP2274442B1 (https=) |
| JP (2) | JP5744719B2 (https=) |
| KR (1) | KR101589511B1 (https=) |
| CN (2) | CN107083391A (https=) |
| AU (1) | AU2009231559B2 (https=) |
| CA (1) | CA2720166A1 (https=) |
| ES (1) | ES2588738T3 (https=) |
| WO (1) | WO2009124312A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12227560B2 (en) | 2016-10-20 | 2025-02-18 | Sanofi | Anti-CHIKV antibodies and uses thereof |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010071610A1 (en) * | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
| EP2374816B1 (en) * | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| WO2011124635A1 (en) | 2010-04-07 | 2011-10-13 | Humalys | Binding molecules against chikungunya virus and uses thereof |
| JP6077450B2 (ja) * | 2010-11-12 | 2017-02-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
| WO2012078116A1 (en) * | 2010-12-10 | 2012-06-14 | Agency For Science, Technology And Research | Immunogenic chikungunya virus peptides |
| EA032364B1 (ru) | 2011-02-11 | 2019-05-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу |
| JP6567824B2 (ja) * | 2011-10-12 | 2019-08-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| EP2712871A1 (en) * | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| WO2014093894A2 (en) | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| AU2014248535B2 (en) | 2013-03-12 | 2017-03-30 | Inovio Pharmaceuticals, Inc. | Improved vaccines for human papilloma virus and methods for using the same |
| EP2968448A4 (en) * | 2013-03-15 | 2016-02-17 | Univ Pennsylvania | COMPOSITIONS USING HYPOXY-INDUCIBLE FACTOR 1-ALPHA AND METHOD OF USE THEREOF |
| US9902765B2 (en) | 2013-07-19 | 2018-02-27 | Integral Molecular, Inc. | Antibodies against chikungunya virus and uses thereof |
| MX2017007187A (es) | 2014-12-01 | 2018-01-30 | Univ Pennsylvania | Construcciones de anticuerpos de adn y metodo para utilizarlas. |
| KR20180138204A (ko) * | 2016-03-21 | 2018-12-28 | 데이비드 비. 웨이너 | Dna 항체 작제물 및 이의 사용 방법 |
| JP6795468B2 (ja) * | 2017-07-14 | 2020-12-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| JP7301811B2 (ja) * | 2017-09-21 | 2023-07-03 | ヴァルネヴァ エスイー | 免疫原性チクングニアウイルスｃｈｉｋｖ－ｄｅｌｔａ ５ｎｓｐ３を含む医薬組成物を製造する方法 |
| WO2019148086A1 (en) * | 2018-01-26 | 2019-08-01 | The Wistar Institute Of Anatomy And Biology | Vaccines against mosquito-borne viruses, and methods of using same |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| JP7680358B2 (ja) * | 2019-01-30 | 2025-05-20 | ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー | 癌抗原を標的とするｄｎａコード化二重特異性ｔ細胞エンゲージャーおよび癌治療薬における使用方法 |
| KR102202082B1 (ko) | 2019-09-25 | 2021-01-11 | 충북대학교 산학협력단 | 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| JP7075130B2 (ja) * | 2019-10-25 | 2022-05-25 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| KR102864666B1 (ko) | 2025-04-21 | 2025-09-29 | 대한민국 | 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| WO1990010693A1 (en) | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Recombinant poxvirus host selection system |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ES2090129T3 (es) | 1989-03-31 | 1996-10-16 | Univ Washington | Vacunas que contienen microorganismos tipo phop avirulentos. |
| EP0431668B1 (en) | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
| US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5810762A (en) | 1995-04-10 | 1998-09-22 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| CA2285056C (en) | 1997-04-03 | 2004-12-14 | Iacob Mathiesen | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6778853B1 (en) | 1997-12-17 | 2004-08-17 | University Of South Florida | Electroporation device |
| US6135990A (en) | 1997-12-17 | 2000-10-24 | University Of South Florida | Electroporation device and method |
| US6120493A (en) | 1998-01-27 | 2000-09-19 | Genetronics, Inc. | Method for the introduction of therapeutic agents utilizing an electroporation apparatus |
| AU3973599A (en) | 1998-05-08 | 1999-11-29 | Genetronics, Inc. | Electrically induced vessel vasodilation |
| US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
| US6697669B2 (en) | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| AU2002211490A1 (en) | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| EP1457211A4 (en) * | 2001-11-20 | 2006-06-14 | Japan Science & Tech Agency | RECOMBINANT VACCINIA VIRUS VACCINE |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7078218B2 (en) | 2002-12-13 | 2006-07-18 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
| EP1633372B1 (en) | 2003-06-13 | 2011-11-30 | The Trustees of The University of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
| NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| CA2545597A1 (en) * | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| CN101516395B (zh) | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
| CA2666501C (en) | 2006-10-17 | 2017-03-21 | Vgx Pharmaceuticals, Inc. | Electroporation devices and methods of using same for electroporation of cells in mammals |
| EP2370455B1 (en) | 2008-11-26 | 2019-07-03 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Virus like particle compositions and methods of use |
-
2009
- 2009-04-06 CA CA2720166A patent/CA2720166A1/en not_active Abandoned
- 2009-04-06 WO PCT/US2009/039656 patent/WO2009124312A2/en not_active Ceased
- 2009-04-06 JP JP2011503242A patent/JP5744719B2/ja not_active Expired - Fee Related
- 2009-04-06 KR KR1020107024734A patent/KR101589511B1/ko not_active Expired - Fee Related
- 2009-04-06 CN CN201611044710.XA patent/CN107083391A/zh active Pending
- 2009-04-06 EP EP09727698.4A patent/EP2274442B1/en not_active Not-in-force
- 2009-04-06 AU AU2009231559A patent/AU2009231559B2/en not_active Ceased
- 2009-04-06 CN CN2009801128936A patent/CN101990580A/zh active Pending
- 2009-04-06 US US12/936,186 patent/US8852609B2/en active Active
- 2009-04-06 ES ES09727698.4T patent/ES2588738T3/es active Active
-
2015
- 2015-01-23 JP JP2015011205A patent/JP2015083017A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12227560B2 (en) | 2016-10-20 | 2025-02-18 | Sanofi | Anti-CHIKV antibodies and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110104198A1 (en) | 2011-05-05 |
| AU2009231559A2 (en) | 2012-07-12 |
| WO2009124312A2 (en) | 2009-10-08 |
| CN107083391A (zh) | 2017-08-22 |
| EP2274442A4 (en) | 2011-10-05 |
| KR20100135879A (ko) | 2010-12-27 |
| WO2009124312A3 (en) | 2010-01-14 |
| CA2720166A1 (en) | 2009-10-08 |
| JP5744719B2 (ja) | 2015-07-08 |
| JP2011516070A (ja) | 2011-05-26 |
| EP2274442A2 (en) | 2011-01-19 |
| JP2015083017A (ja) | 2015-04-30 |
| AU2009231559B2 (en) | 2015-10-22 |
| KR101589511B1 (ko) | 2016-02-01 |
| EP2274442B1 (en) | 2016-06-29 |
| CN101990580A (zh) | 2011-03-23 |
| AU2009231559A1 (en) | 2009-10-08 |
| US8852609B2 (en) | 2014-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2588738T3 (es) | Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas | |
| ES2685435T3 (es) | Nuevas vacunas frente a múltiples subtipos del virus del dengue | |
| US12419945B2 (en) | Vaccines against Zika virus | |
| JP6333730B2 (ja) | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 | |
| JP2023510112A (ja) | アフリカ豚熱ウイルスに対するワクチン、およびそれを使用する方法 | |
| JP2021506300A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物 | |
| AU2014228497B2 (en) | Novel vaccines against multiple subtypes of dengue virus | |
| WO2018195447A1 (en) | Recombinant mva-based hiv immunogens and uses thereof | |
| JP2016516075A (ja) | 結核の予防または治療用の合成免疫原 | |
| US20250041386A1 (en) | Recombinant Interleukin 12 Construct and Uses Thereof | |
| HK1219904A1 (zh) | 针对多种登革病毒亚型的新颖疫苗 | |
| CA3141323C (en) | Recombinant interleukin 12 construct and uses thereof | |
| WO2019148086A1 (en) | Vaccines against mosquito-borne viruses, and methods of using same | |
| PT1605971E (pt) | COMPOSIÆO IMUNOGéNICA E MéTODOS | |
| HK1155208A (en) | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |